In a challenging market environment, Centrexion Therapeutics Corp stock has touched a 52-week low, with shares falling to $0.9. According to InvestingPro data, the stock shows significant volatility ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.

Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...

Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...

(RTTNews) - Context Therapeutics Inc. (CNTX), a biopharmaceutical company, Monday announced, that it has appointed Andy Pasternak as Chairman of its Board of Directors. Pasternak succeeds Richard ...